Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

inal tract (29%), allergic rhinitis (29%), acne-like skin inflammation (25%), pharyngitis or inflammation of the pharynx (25%), vomiting (25%), abnormal behavior (21%), cough (21%), dry skin (21%), scratching of the skin (21%), external ear infection (21%) and skin infection (21%). The most common Grade 3 AEs (with an incidence of at least 5%) were stomatitis or mouth sores, convulsion and decreased neutrophil count. In addition, single cases of Grade 3 sinusitis, pneumonia, viral bronchitis, gastroenteritis or inflammation of the gastrointestinal tract, limb abscess, aspiration, cyclic neutropenia, post lumbar puncture syndrome, sleep apnea syndrome and dizziness were reported. A single case of Grade 4 convulsion was reported. Adverse events were mostly Grade 1 (mild) or Grade 2 (moderate) in severity and were consistent with those previously reported at six months(11).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Everolimus is approved in Switzerland as Votubia® (everolimus) tablets for the treatment of patients three years of age and older, with SEGA associated with TS, for whom surgery is not a suitable option. Should everolimus be approved in the EU, the trade name will be Votubia.

Afinitor is approved in the US and Switzerland for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and also in the EU for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is approved in the US f
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... India, Oct. 19 Cardiac Science Corporation (Nasdaq: ... NSE: OPTOCIRCUI] today announced they have entered into a definitive ... all of the outstanding shares of Cardiac Science common stock ... 10% premium to the closing price of Cardiac Science common ...
... 18 Althea Technologies, Inc., a leading provider ... parenteral drug products, announced today that it has ... high-speed syringe filling line.  This line is located ... in San Diego. The expanded capacity complements existing ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... older Americans suffer from depression, often brought on by ... a project that followed the lives of thousands ... that Internet use among the elderly can reduce the ... "That,s a very strong effect," said Shelia Cotten, a ... media who led the project. "And it all has ...
(Date:4/17/2014)... NEW YORK April 17, 2014 EcoHealth Alliance, ... public health issues, published a comprehensive review today examining ... and Marburg virus. The review calls for improved global ... such as the recent outbreak of Ebola in West ... in the countries of Guinea and Liberia. According ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... Medical Researchers at the University of Alberta reported today evidence ... as potential therapy for perhaps the deadliest of all human ... is published at the journal Science Translational Medicine , ... Science; it appears today at the journal,s web site ...
... University have developed a new way of performing lab ... prostate cancer treatment. It will allow them to identify ... that is associated with an aggressive group of prostate ... uses DNA probes to analyze the three-dimensional space cancer ...
... ... New Products, Industry Related News and Educational Material. BW Clifford Specializes in Wholesale ... ... expansion of their candy store , ( http://www.bwcliffordcandy.com ). BW Clifford specializes ...
... Members Are ... ... This week the Association of Farmworker Opportunity Programs , (AFOP) SAFE AmeriCorps Program is ... encourage others to make a commitment to serve and raise awareness concerning community needs. ...
... ... the skaters, but has shown to have a significant effect on top charities around the world. ... (PRWEB) May 12, 2010-- ... is not only supporting the sport and the skaters, but has shown to have a significant ...
... the rate of peanut allergies in children more than tripled ... May 12 issue of the Journal of Allergy and ... Professor of Pediatrics, Jaffe Food Allergy Institute at,Mount Sinai School ... 13,534 individuals in 2008, a response rate of 42 percent. ...
Cached Medicine News:Health News:DCA research on brain cancer 2Health News:DCA research on brain cancer 3Health News:Online Candy Store BW Clifford Launches New Candy Lines and Industry News Resources 2Health News:AFOP's SAFE AmeriCorps Collecting Clothes for Our Country's Farmworkers 2Health News:Go Skateboarding Day Benefits Top Charities Across The Globe 2Health News:Go Skateboarding Day Benefits Top Charities Across The Globe 3Health News:Rate of childhood peanut allergies more than tripled from 1997 to 2008 2
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Medicine Products: